USA flag logo/image

An Official Website of the United States Government

Automated Macrodissection Device

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43GM101790
Solicitation Year:
2012
Solicitation Topic Code:
NIGMS
Solicitation Number:
PA11-096
Small Business Information
AVANSCI BIO, LLC
1290 W 2320 S, STE D SALT LAKE CITY, UT 84119-1476
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: Automated Macrodissection Device
Agency: HHS
Contract: 1R43GM101790-01
Award Amount: $147,726.00
 

Abstract:

DESCRIPTION (provided by applicant): Microscopic examination of formalin fixed, paraffin embedded (FFPE) tissue sections mounted on glass slides is the cornerstone of clinical histopathology. Ancillary molecular testing is often required for diagnosis, risk stratification, ad treatment planning, particularly in cancer. Molecular testing often involves mutation or expression analysis of nucleic acids (DNA and RNA) recovered from FFPE tissue sections. Due to tissue heterogeneity, nucleic acids are often isolated from dissected regions of the FFPE tissue section using current dissection methods, including: Manual Macrodissection, Manual Microdissection, and Laser Capture Microdissection (LCM). This Phase I grant application is for the development of an Automated Macrodissection Device for clinicians that significantly advances productivity and quality of results ahead of existing competitive devices and methods. The goal of the proposed Phase I project is to develop a novel system that encompasses a software application and user interface that will allow a pathologist to indicate an area of interet on a digital image of a tissue section. The software will transfer that area of interest to secondary slides on a new fully automated 12 slide tissue removal and recovery instrument. The new instrument will be a computer controlled system that will includes x.y.z positioning, integrated optics, and multiple choices of specialized tissue removal and recovery tips. Using image recognition the system will automatically identify the tissue section area of interest on the secondary slide, move the specialized tip over this area to displace tissue fragments from the slide surface, and simultaneously recover the liquid containing the suspended tissue section fragments for theancillary molecular testing. The system will be based on dissection technology co.invented and exclusively licensed from the University of Utah's ARUP Laboratories. The subsequent commercial instrument would fill the need in the clinical market for a highthroughput macrodissection (down to 0.25mm resolution) instrument with full automation, process monitoring and reporting, ease of use, with the recovery efficiency of manual dissection techniques, but with far better precision. The system will be validatedfor tissue image recognition capability, slide to slide scaling and registration, and the capability for integrationto primary digital pathology imaging systems. The system will also be validated for mechanical automation performance including both slidefiducial and automated x.y. correction protocols for 12 slides as well as automated consumable loading and sample handling. Ultimately, the system will also be validated for dissection resolution, efficiency, and accuracy of tissue recovery. Validation strategies are defined based on a model system of digitally imaging system, 12 slide batches, and a defined set of tissue types and slide types. By quantifying the imaging, mechanical and dissection performance in Phase I on prototype instruments, we will demonstrate feasibility for Phase II development and commercialization. PUBLIC HEALTH RELEVANCE: The Automated Macrodissection Device will provide a highly affordable automated system for integrated digital slide imaging and walk-away tissue dissection and recovery for up to twelve slides per batch. The integrated imaging will expedite pathologist review of slides requiring microdissection and will enable consultation with expert pathologists via digital pathology. The system will improve process documentation and verification, enhancing the efforts toward electronic medical records. The device's technical performance includes a dissection resolution down to 0.25mm and an order of magnitude lower investment than that required for laser capture microdissection technologies, enabling much broader access to the new technology. The new device will promote productivity and quality of results for clinicians working in cancer diagnostics, as well as diverse areas of cancer and non-cancer research requiring high throughput tissue dissection from slides.

Principal Investigator:

Nils B. Adey
801-232-9200
nils@avanscibio.com

Business Contact:

Robert J. Parry
435-901-4516
rparry@avanscibio.com
Small Business Information at Submission:

AVANSCI BIO, LLC
1290 W 2320 S, STE D SALT LAKE CITY, UT 84119-1476

EIN/Tax ID: 127475944
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No